Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Qualigen Therapeutics stock price, quote, forecast and news

QLGN
US74754R1032
A2P5C5

Price

0.17
Today +/-
+0.01
Today %
+3.64 %
P

Qualigen Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Qualigen Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Qualigen Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Qualigen Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Qualigen Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Qualigen Therapeutics Stock Price History

DateQualigen Therapeutics Price
9/16/20240.17 undefined
9/13/20240.16 undefined
9/12/20240.16 undefined
9/11/20240.16 undefined
9/10/20240.15 undefined
9/9/20240.16 undefined
9/6/20240.16 undefined
9/5/20240.16 undefined
9/4/20240.18 undefined
9/3/20240.19 undefined
8/30/20240.19 undefined
8/29/20240.19 undefined
8/28/20240.19 undefined
8/27/20240.20 undefined
8/26/20240.20 undefined
8/23/20240.20 undefined
8/22/20240.21 undefined
8/21/20240.20 undefined
8/20/20240.21 undefined
8/19/20240.22 undefined

Qualigen Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Qualigen Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Qualigen Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Qualigen Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Qualigen Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Qualigen Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Qualigen Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Qualigen Therapeutics’s growth potential.

Qualigen Therapeutics Revenue, EBIT and net profit per share

DateQualigen Therapeutics RevenueQualigen Therapeutics EBITQualigen Therapeutics Net Income
2026e9.79 M undefined-18.07 M undefined-6.07 M undefined
2025e0 undefined-11.63 M undefined-8.81 M undefined
2024e0 undefined-11.22 M undefined-12.4 M undefined
20230 undefined-11.3 M undefined-13.42 M undefined
20224.98 M undefined-17.94 M undefined-18.64 M undefined
20215.65 M undefined-22.66 M undefined-17.9 M undefined
20202.85 M undefined-10.52 M undefined-19.55 M undefined
20190 undefined-10.84 M undefined-10.13 M undefined
20180 undefined-17 M undefined-19.41 M undefined
20170 undefined-7.9 M undefined-10.97 M undefined
20160 undefined-18.45 M undefined-18.38 M undefined
20150 undefined-8.91 M undefined-9.18 M undefined
20140 undefined-2.28 M undefined-3.07 M undefined
20130 undefined-2.11 M undefined-2.64 M undefined
20120 undefined-3.4 M undefined-3.81 M undefined
20110 undefined-3.4 M undefined-3.81 M undefined

Qualigen Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e
0000000002540009
----------150.00-20.00----
----------20.00-----
00000000001,00000000
-3-3-2-2-8-18-7-17-10-10-22-17-11-11-11-18
----------500.00-440.00-425.00----200.00
-3-3-2-3-9-18-10-19-10-19-17-18-13-12-8-6
---33.3350.00200.00100.00-44.4490.00-47.3790.00-10.535.88-27.78-7.69-33.33-25.00
0000000.010.020.041.742.933.845.07000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Qualigen Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Qualigen Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
1.770.452.7515.827.0522.6314.81.75.9523.9817.547.030.4
0000000006208205400
0000000000000
0000000000.951.061.590
0.080.080.060.190.160.170.420.510.182.681.381.660.76
1.850.532.8116.017.2122.815.222.216.1328.2320.810.821.17
00.010.010.020.020.020.020.110.080.71.851.770
0000000000000
0000000000000
0000000000.190.175.850
000000000006300
102015010101020480480202020866.48
0.010.030.160.030.030.030.040.590.560.912.048.270.87
1.860.562.9716.047.2422.8315.262.86.6929.1422.8419.092.03
                         
0.010.010.010.010.015.188.091.550.290.030.040.040.04
2.032.063.441.7649.5668.2871.5179.8986.7385.11101.27110.53114.66
-12.19-14.83-17.9-27.08-45.47-53.33-70.2-80.33-82-66.85-84.74-103.39-116.8
00000000000500
0000000000000
-10.15-12.76-14.4914.694.120.139.41.115.0218.2916.577.23-2.1
0.750.831.080.741.92.244.511.421.290.50.890.862.22
0.030.030.170.611.220.451.410.280.380.971.861.930.53
00000.010.020.01008.831.894.870.09
0.130.030000000000.951.3
000000000130000
0.910.891.251.353.132.715.931.71.6710.434.648.614.14
11.0912.4116.20000000.01000
000000000003600
0000000000.41.641.350
11.0912.4116.20000000.411.641.710
1213.317.451.353.132.715.931.71.6710.846.2810.324.14
1.850.542.9616.047.2322.8415.332.816.6929.1322.8517.552.03
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Qualigen Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Qualigen Therapeutics's financial health and stability.

Assets

Qualigen Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Qualigen Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Qualigen Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Qualigen Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192019202020212022
-3-3-2-2-8-18-7-16-1-10-19-17-21
0000000000000
0000000000000
000001030-4-210
00003100001217
0000000000000
0000000000000
-3-3-1-1-5-15-7-13-1-14-10-14-13
0000000000000
0000000-607000
0000000-607000
0000000000000
1,0001,00000000000000
2203217256513590
4403186225513482
0000-20-2000-102
0000000000000
11-1213-815-144-623-6-10
-3.08-3.08-1.97-1.16-5.74-15.22-7.41-13.33-1.16-14.52-10.37-14.87-13.57
0000000000000

Qualigen Therapeutics stock margins

The Qualigen Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Qualigen Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Qualigen Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Qualigen Therapeutics's sales revenue. A higher gross margin percentage indicates that the Qualigen Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Qualigen Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Qualigen Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Qualigen Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Qualigen Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Qualigen Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Qualigen Therapeutics Margin History

Qualigen Therapeutics Gross marginQualigen Therapeutics Profit marginQualigen Therapeutics EBIT marginQualigen Therapeutics Profit margin
2026e13.65 %-184.59 %-62.02 %
2025e13.65 %0 %0 %
2024e13.65 %0 %0 %
202313.65 %0 %0 %
202213.65 %-360.24 %-374.3 %
202123.36 %-401.06 %-316.81 %
20207.37 %-369.12 %-685.96 %
201913.65 %0 %0 %
201813.65 %0 %0 %
201713.65 %0 %0 %
201613.65 %0 %0 %
201513.65 %0 %0 %
201413.65 %0 %0 %
201313.65 %0 %0 %
201213.65 %0 %0 %
201113.65 %0 %0 %

Qualigen Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Qualigen Therapeutics earnings per share therefore indicates how much revenue Qualigen Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Qualigen Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Qualigen Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Qualigen Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Qualigen Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Qualigen Therapeutics Revenue, EBIT and net profit per share

DateQualigen Therapeutics Sales per ShareQualigen Therapeutics EBIT per shareQualigen Therapeutics Earnings per Share
2026e0.8 undefined0 undefined-0.5 undefined
2025e0 undefined0 undefined-0.72 undefined
2024e0 undefined0 undefined-1.02 undefined
20230 undefined-2.23 undefined-2.64 undefined
20221.3 undefined-4.67 undefined-4.85 undefined
20211.93 undefined-7.73 undefined-6.11 undefined
20201.64 undefined-6.05 undefined-11.24 undefined
20190 undefined-271 undefined-253.25 undefined
20180 undefined-850 undefined-970.5 undefined
20170 undefined-790 undefined-1,097 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined

Qualigen Therapeutics business model

Qualigen Therapeutics is a company that specializes in the development and production of innovative therapeutics, diagnostics, and medical devices. It was founded in 1995 and has since become a major player in the bio-pharmaceutical industry. The company focuses on the development of oncology products and has expanded its portfolio to include a wide range of products and services for various disease conditions. It markets its products and services through collaborations with institutions and companies worldwide. The company is divided into different divisions, including oncology, infectious diseases, immunology, and metabolic disorders, each offering innovative products and services tailored to specific clinical needs. In the oncology division, Qualigen Therapeutics develops therapeutics for the treatment of cancer, including a novel lung cancer medication. It has also developed a promising therapy for COVID-19. In the infectious diseases division, the company focuses on the development of diagnostics and therapeutics for the treatment of infectious diseases, such as a rapid HIV test and a novel medication for tuberculosis. The immunology division focuses on the development of diagnostics and therapeutics for autoimmune diseases, including a diagnostic test for rheumatoid arthritis and a novel medication for multiple sclerosis. In the metabolic disorders division, the company develops diagnostics and therapeutics for conditions like diabetes, including a diagnostic test for diabetes and a novel medication for obesity. Qualigen Therapeutics is an innovative and forward-thinking company that specializes in the development and production of therapeutics, diagnostics, and medical devices. It collaborates with various institutions and companies worldwide to market its products and services. Its different divisions offer a wide range of innovative products and services tailored to specific clinical needs. Qualigen Therapeutics is one of the most popular companies on Eulerpool.com.

Qualigen Therapeutics SWOT Analysis

Strengths

  • Strong portfolio of advanced therapeutics and diagnostic technologies.
  • Well-established reputation in the biopharmaceutical industry.
  • Experienced and knowledgeable leadership team.
  • Robust research and development capabilities.

Weaknesses

  • Relatively small compared to major pharmaceutical companies, limiting resources.
  • Limited market presence and brand recognition.
  • Dependency on external funding for clinical trials and commercialization efforts.
  • Potential vulnerability to changes in regulations and patent issues.

Opportunities

  • Increasing demand for innovative therapeutics and diagnostics.
  • Collaboration opportunities with larger pharmaceutical companies.
  • Expanding into emerging markets with unmet medical needs.
  • Growing trend towards personalized medicine and precision diagnostics.

Threats

  • Intense competition from established pharmaceutical companies.
  • Regulatory and legal challenges in the healthcare industry.
  • Potential disruptions in the supply chain or manufacturing processes.
  • Rapidly evolving technological landscape necessitating continuous innovation.

Qualigen Therapeutics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Qualigen Therapeutics Revenue by Segment

Segmente20222021
Net Product Sales-5.02 M USD
License Revenue-632,000 USD
Net Product Sales4.98 M USD-
Collaborative Research Revenue--

Qualigen Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Qualigen Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Qualigen Therapeutics shares outstanding

The number of shares was Qualigen Therapeutics in 2023 — This indicates how many shares 5.073 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Qualigen Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Qualigen Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Qualigen Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Qualigen Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Qualigen Therapeutics Stock splits

In Qualigen Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Qualigen Therapeutics.

Qualigen Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.94 -0.08  (91.47 %)2023 Q3
6/30/2023-0.53 -0.68  (-28.21 %)2023 Q2
9/30/2022-1.33 -1  (24.59 %)2022 Q3
6/30/2022-1.63 -1.1  (32.6 %)2022 Q2
3/31/2022-1.73 -1.2  (30.8 %)2022 Q1
12/31/2021-1.73 -2  (-15.34 %)2021 Q4
9/30/2021-1.99 -1  (49.72 %)2021 Q3
6/30/2021-1.63 -1.8  (-10.29 %)2021 Q2
3/31/2021-1.43 -1.3  (8.96 %)2021 Q1
12/31/2019-15.3 -9.5  (37.91 %)2019 Q4
1
2
3

Qualigen Therapeutics list of shareholders

%
Name
Stocks
Change
Date
4.56542 % Alpha Capital Aktiengesellschaft555,15505/15/2023
0.34453 % Geode Capital Management, L.L.C.41,895012/31/2023
0.28601 % Citadel Advisors LLC34,77934,77912/31/2023
0.21250 % BlackRock Institutional Trust Company, N.A.25,840012/31/2023
0.18772 % The Vanguard Group, Inc.22,827012/31/2023
0.17287 % Poirier (Michael S)21,02105/15/2023
0.08988 % State Street Global Advisors (US)10,930012/31/2023
0.06586 % HighMark Wealth Management LLC8,009012/31/2023
0.06247 % Northern Trust Global Investments7,596012/31/2023
0.04326 % Tower Research Capital LLC5,26030512/31/2023
1
2
3
4
...
5

Qualigen Therapeutics Executives and Management Board

Mr. Christopher Lotz58
Qualigen Therapeutics Chief Financial Officer, Vice President - Finance
Compensation 2.95 M
Dr. Wajdi Abdul-Ahad70
Qualigen Therapeutics Chief Scientific Officer, Vice President - Research and Development
Compensation 2.24 M
Mr. Michael Poirier67
Qualigen Therapeutics Chairman of the Board, Chief Executive Officer (since 2020)
Compensation 728,454
Dr. Tariq Arshad53
Qualigen Therapeutics Senior Vice President, Chief Medical Officer
Compensation 439,650
Mr. Ira Ritter74
Qualigen Therapeutics Director (since 2020)
Compensation 95,496
1
2

Most common questions regarding Qualigen Therapeutics

What values and corporate philosophy does Qualigen Therapeutics represent?

Qualigen Therapeutics Inc represents values of innovation, dedication, and commitment to improving patient outcomes. The company's corporate philosophy revolves around developing novel therapeutic solutions that address unmet medical needs. They aim to leverage their expertise in biotechnology to create effective treatments for various diseases, including cancer and infectious diseases. Qualigen Therapeutics Inc prioritizes excellence in scientific research, clinical development, and commercialization to provide high-quality and accessible healthcare solutions. The company values integrity, collaboration, and patient-centered care, striving to make a positive impact on the lives of patients worldwide with its advanced therapies.

In which countries and regions is Qualigen Therapeutics primarily present?

Qualigen Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Qualigen Therapeutics achieved?

Qualigen Therapeutics Inc has achieved several significant milestones. One of the notable accomplishments is the development of their FDA-approved FastPack® System, which enables rapid testing for a range of diseases. The company has also made progress in developing their proprietary oligonucleotide nanoparticle drug delivery technology. Additionally, Qualigen Therapeutics has actively conducted clinical trials for various therapeutic candidates, including their lead drug candidate, AS1411. They have also forged partnerships and collaborations with research institutions and pharmaceutical companies for the advancement of their products. Overall, Qualigen Therapeutics Inc has demonstrated its commitment to innovation and contributing to the field of healthcare.

What is the history and background of the company Qualigen Therapeutics?

Qualigen Therapeutics Inc is a biotechnology company that specializes in the development and commercialization of innovative cancer therapeutics, diagnostics, and medical devices. Founded in 1996, Qualigen has a rich history of researching and developing novel technologies to address significant unmet needs in the medical industry. The company has made notable advancements in the fields of infectious diseases, women's health, and oncology. With a strong focus on precision medicine and personalized treatments, Qualigen Therapeutics Inc has positioned itself as a key player in the healthcare industry. Continuously striving to improve patient outcomes, the company remains dedicated to advancing the science of diagnosis and treatment.

Who are the main competitors of Qualigen Therapeutics in the market?

The main competitors of Qualigen Therapeutics Inc in the market include other biopharmaceutical companies operating in the same therapeutic areas. Key competitors may vary based on the specific products and services offered by Qualigen Therapeutics Inc. Some prominent competitors in the biopharmaceutical industry include Pfizer Inc, Johnson & Johnson, Moderna Inc, and Novartis AG.

In which industries is Qualigen Therapeutics primarily active?

Qualigen Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Qualigen Therapeutics?

The business model of Qualigen Therapeutics Inc. centers around the development and commercialization of innovative therapeutic products. Specifically, the company focuses on the discovery and advancement of novel treatments for cancer and infectious diseases. By leveraging its proprietary technologies and expertise, Qualigen Therapeutics aims to address unmet medical needs and improve patient outcomes. This includes the development of next-generation therapeutics, diagnostics, and drug delivery systems. The company's commitment to research, development, and collaboration with strategic partners positions Qualigen Therapeutics as a leading player in the field of biotechnology, with a strong emphasis on advancing patient care and revolutionizing healthcare solutions.

What is the P/E ratio of Qualigen Therapeutics 2024?

The Qualigen Therapeutics P/E ratio is -0.07.

What is the P/S ratio of Qualigen Therapeutics 2024?

The Qualigen Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Qualigen Therapeutics?

The AlleAktien quality score for Qualigen Therapeutics is 5/10.

What is the revenue of Qualigen Therapeutics 2024?

The revenue cannot currently be calculated for Qualigen Therapeutics.

How high is the profit of Qualigen Therapeutics 2024?

The expected Qualigen Therapeutics profit is -12.4 M USD.

What is the business model of Qualigen Therapeutics

Qualigen Therapeutics Inc is an emerging biotechnology company based in the USA. The company focuses on the development and commercialization of innovative therapeutics and diagnostics. Its business activities cover a wide range of products and services in various medical fields. Qualigen Therapeutics' business model is tailored to its various areas of activity. Firstly, the company is engaged in the development of medical products. Qualigen Therapeutics has a number of patented technologies, including the FastPack® Point-of-Care diagnostic systems, which provide it with a competitive advantage. The company has expertise and experience in medical research and development, enabling it to develop new drugs and diagnostic tools in a short period of time. Another important area is the distribution of medications and medical devices. The company offers a wide range of drugs and diagnostics that can be used, for example, in the treatment of cancer, infections, or autoimmune diseases. Qualigen Therapeutics' business is focused on various market segments, such as clinical diagnostics, as well as the pharmaceutical and biotech industries. Furthermore, through partnerships both domestically and internationally, the company is able to expand its reach to bio-pharmaceutical companies in the USA and global markets. Currently, the company is also heavily focused on the development of COVID-19 tests and therapies. Qualigen has described a low-cost COVID-19 rapid test that can be conducted in just a few minutes. They are also developing a therapy named RAS-F, which targets COVID-19 symptoms promisingly. Overall, as an emerging biotechnology company, Qualigen Therapeutics offers a wide range of medical devices, diagnostic, and therapeutic products in various medical fields. Its business model is designed to gain a competitive advantage in different areas of activity and establish a broad market presence. With its unique and patented technology, strong research expertise, and focus on COVID-19 tests and therapies, Qualigen Therapeutics has the potential to become a significant player in the biotech and pharmaceutical industries.

What is the Qualigen Therapeutics dividend?

Qualigen Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Qualigen Therapeutics pay dividends?

The dividend cannot currently be calculated for Qualigen Therapeutics or the company does not pay out a dividend.

What is the Qualigen Therapeutics ISIN?

The ISIN of Qualigen Therapeutics is US74754R1032.

What is the Qualigen Therapeutics WKN?

The WKN of Qualigen Therapeutics is A2P5C5.

What is the Qualigen Therapeutics ticker?

The ticker of Qualigen Therapeutics is QLGN.

How much dividend does Qualigen Therapeutics pay?

Over the past 12 months, Qualigen Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Qualigen Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Qualigen Therapeutics?

The current dividend yield of Qualigen Therapeutics is .

When does Qualigen Therapeutics pay dividends?

Qualigen Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Qualigen Therapeutics?

Qualigen Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Qualigen Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Qualigen Therapeutics located?

Qualigen Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Qualigen Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Qualigen Therapeutics from 9/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Qualigen Therapeutics pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Qualigen Therapeutics in the year 2023?

In the year 2023, Qualigen Therapeutics distributed 0 USD as dividends.

In which currency does Qualigen Therapeutics pay out the dividend?

The dividends of Qualigen Therapeutics are distributed in USD.

All fundamentals about Qualigen Therapeutics

Our stock analysis for Qualigen Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Qualigen Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.